BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 22613532)

  • 1. Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome.
    Wang YB; Fu XH; Gu XS; Wang XC; Zhao YJ; Hao GZ; Jiang YF; Fan WZ; Wu WL; Li SQ; Xue L
    Chin Med J (Engl); 2012 Mar; 125(6):1063-7. PubMed ID: 22613532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty.
    Geng W; Fu XH; Gu XS; Wang YB; Wang XC; Li W; Jiang YF; Hao GZ; Fan WZ; Xue L
    Chin Med J (Engl); 2012 Oct; 125(19):3368-72. PubMed ID: 23044290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention.
    Zhang J; Fu X; Jia X; Fan X; Gu X; Li S; Wu W; Fan W; Su J; Hao G; Jiang Y; Xue L
    Acta Radiol; 2010 Jul; 51(6):641-8. PubMed ID: 20438292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of contrast-induced nephropathy in diabetics undergoing elective percutaneous coronary intervention: role of the ratio of contrast medium volume to estimated glomerular filtration rate.
    Wang XC; Fu XH; Wang YB; Jia XW; Wu WL; Gu XS; Zhang J; Su JL; Hao GZ; Jiang YF; Fan WZ; Li SQ
    Chin Med J (Engl); 2011 Mar; 124(6):892-6. PubMed ID: 21518598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Xinwei J; Xianghua F; Jing Z; Xinshun G; Ling X; Weize F; Guozhen H; Yunfa J; Weili W; Shiqiang L
    Am J Cardiol; 2009 Aug; 104(4):519-24. PubMed ID: 19660605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
    Bilasy ME; Oraby MA; Ismail HM; Maklady FA
    J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of anisodamine on renal function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Wang Y; Fu X; Wang X; Jia X; Gu X; Zhang J; Su J; Hao G; Jiang Y; Fan W; Wu W; Li S
    Tohoku J Exp Med; 2011 Jun; 224(2):91-7. PubMed ID: 21597242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome.
    Senoo T; Motohiro M; Kamihata H; Yamamoto S; Isono T; Manabe K; Sakuma T; Yoshida S; Sutani Y; Iwasaka T
    Am J Cardiol; 2010 Mar; 105(5):624-8. PubMed ID: 20185007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
    Worasuwannarak S; Pornratanarangsi S
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
    Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of iso-osmolar contrast use in emergent percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Kanei Y; Ayabe K; Ratcliffe J; Vales L; Nakra N; Friedman P; Fox J
    J Invasive Cardiol; 2011 Nov; 23(11):448-50. PubMed ID: 22045075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Influence of intracoronary administration of anisodamine on no-reflow, ventricular function and systolic synchrony in acute myocardial infarction patients undergoing percutaneous coronary intervention].
    Fan WZ; Fu XH; Jiang YF; Gu XS; Wu WL; Li SQ; Liu J; Xue L; Wei YY; Hao GZ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Oct; 35(10):908-13. PubMed ID: 18206037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention.
    Ochoa A; Pellizzon G; Addala S; Grines C; Isayenko Y; Boura J; Rempinski D; O'Neill W; Kahn J
    J Interv Cardiol; 2004 Jun; 17(3):159-65. PubMed ID: 15209578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy.
    Kinbara T; Hayano T; Ohtani N; Furutani Y; Moritani K; Matsuzaki M
    J Cardiol; 2010 Mar; 55(2):174-9. PubMed ID: 20206069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrast medium dose-to-GFR ratio: a measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention.
    Nyman U; Björk J; Aspelin P; Marenzi G
    Acta Radiol; 2008 Jul; 49(6):658-67. PubMed ID: 18568558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Contrast induced nephropathy in acute coronary syndrome].
    Carnevalini M; Giorgi M; Waldman S; Caturla N; Ovejero R; Falconi E; San Miguel L; Caroli C; Magariños E; Cohen Arazi H
    Medicina (B Aires); 2011; 71(5):441-8. PubMed ID: 22057170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention.
    Li W; Fu X; Wang Y; Li X; Yang Z; Wang X; Geng W; Gu X; Hao G; Jiang Y; Fan W; Wu W; Li S
    Cardiology; 2012; 122(3):195-202. PubMed ID: 22854323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrast nephropathy in high-risk patients undergoing coronary angiography and intervention.
    Uddin MA; Rabbani MA; Jafary FH; Bhatti MA; Islam M
    J Coll Physicians Surg Pak; 2005 Dec; 15(12):791-4. PubMed ID: 16398973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.